Literature DB >> 15095287

Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization.

Yuji Oshima1, Kyoichi Takahashi, Sachiko Oshima, Yoshitsugu Saishin, Yumiko Saishin, Raquel Lima Silva, Xaoling Liang, P Seshidhar Reddy, Shanthi Ganesh, Terrence Brann, Gene Liau, Michael Kaleko, Sheila Connelly, Peter A Campochiaro.   

Abstract

Vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) have been implicated as important stimulatory factors for retinal neovascularization. In this study, we used intraocular gene transfer with gutless adenoviral (AGV) vectors to determine the effect of increased intraocular expression of VEGF, IGF-1, or sphingosine kinase (SPK), which produces sphingosine-1-phosphate, another angiogenic factor. Retinal neovascularization did not occur from intravitreous AGV-vectored VEGF, IGF-1, SPK, or combined VEGF and IGF-1, except occasionally adjacent to the retinal penetration site from the injection. However, corneal and iris neovascularization occurred after 2 weeks in all eyes injected with AGV.VEGF, but not those injected with only AGV.IGF-1 or AGV.SPK. These data suggest that the superficial capillary bed of the retina is relatively insensitive to VEGF, IGF-1, or SPK in adult mice, except when combined with retinal trauma. However, AGV-vectored VEGF is sufficient to consistently cause severe corneal and iris neovascularization. This provides a model for anterior segment neovascularization, which unlike previous models is relatively inexpensive and is not plagued by spontaneous regression, and therefore, may be useful for identification of new treatments. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095287     DOI: 10.1002/jcp.10441

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases.

Authors:  Lynn W Maines; Kevin J French; Ellen B Wolpert; David A Antonetti; Charles D Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

2.  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.

Authors:  Jikui Shen; Maike Frye; Bonnie L Lee; Jessica L Reinardy; Joseph M McClung; Kun Ding; Masashi Kojima; Huiming Xia; Christopher Seidel; Raquel Lima e Silva; Aling Dong; Sean F Hackett; Jiangxia Wang; Brian W Howard; Dietmar Vestweber; Christopher D Kontos; Kevin G Peters; Peter A Campochiaro
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

Review 3.  Molecular pathogenesis of retinal and choroidal vascular diseases.

Authors:  Peter A Campochiaro
Journal:  Prog Retin Eye Res       Date:  2015-06-23       Impact factor: 21.198

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.